Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Marks

Showing results (771-780 of 986) with videos related to

Pageof 99
Sort By:
Ecology and Evolution|March 28, 2013
River barriers and cryptic biodiversity in an evolutionary museumG Voelker, B D Marks, C Kahindo, et al.
Biochimica Et Biophysica Acta|August 17, 2002
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosisUlrik B Nielsen, Dmitri B Kirpotin, Edward M Pickering, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2002
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibodyA Nowakowski, C Wang, D B Powers, et al.
The Journal of Pediatrics|June 24, 2005
Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disordersStephen D Marks, M Patricia Massicotte, Brian T Steele, et al.
Pediatric Nephrology (Berlin, Germany)|June 18, 2021
Outcomes of paediatric kidney transplant recipients using the updated 2013/2017 Banff histopathological classification for antibody-mediated rejectionEvgenia Preka, Thivya Sekar, Sergio C Lopez Garcia, et al.
Expert Opinion on Therapeutic Targets|July 23, 2004
Development of ligand-targeted liposomes for cancer therapyCharles O Noble, Dmitri B Kirpotin, Mark E Hayes, et al.
Journal of Molecular Biology|February 9, 2010
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding regionJianbo Dong, Aaron A Thompson, Yongfeng Fan, et al.
BMJ (Clinical Research Ed.)|July 5, 1997
Britain's first minister of public health. National centre for public health is neededJ Powles, N Day, K McPherson, et al.
Molecular Cancer Therapeutics|May 9, 2012
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodiesYu Zhou, Anne-Laure Goenaga, Brian D Harms, et al.
Journal of Molecular Biology|November 8, 1996
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding siteR Schier, A McCall, G P Adams, et al.
Pageof 99

Showing results (771-780 of 986) with videos related to

Sort By:
Pageof 99
Ecology and Evolution|March 28, 2013
River barriers and cryptic biodiversity in an evolutionary museumG Voelker, B D Marks, C Kahindo, et al.
Biochimica Et Biophysica Acta|August 17, 2002
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosisUlrik B Nielsen, Dmitri B Kirpotin, Edward M Pickering, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2002
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibodyA Nowakowski, C Wang, D B Powers, et al.
The Journal of Pediatrics|June 24, 2005
Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disordersStephen D Marks, M Patricia Massicotte, Brian T Steele, et al.
Pediatric Nephrology (Berlin, Germany)|June 18, 2021
Outcomes of paediatric kidney transplant recipients using the updated 2013/2017 Banff histopathological classification for antibody-mediated rejectionEvgenia Preka, Thivya Sekar, Sergio C Lopez Garcia, et al.
Expert Opinion on Therapeutic Targets|July 23, 2004
Development of ligand-targeted liposomes for cancer therapyCharles O Noble, Dmitri B Kirpotin, Mark E Hayes, et al.
Journal of Molecular Biology|February 9, 2010
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding regionJianbo Dong, Aaron A Thompson, Yongfeng Fan, et al.
BMJ (Clinical Research Ed.)|July 5, 1997
Britain's first minister of public health. National centre for public health is neededJ Powles, N Day, K McPherson, et al.
Molecular Cancer Therapeutics|May 9, 2012
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodiesYu Zhou, Anne-Laure Goenaga, Brian D Harms, et al.
Journal of Molecular Biology|November 8, 1996
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding siteR Schier, A McCall, G P Adams, et al.
Pageof 99